Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Lancet Infect Dis. 2021 Nov 18;22(3):377–389. doi: 10.1016/S1473-3099(21)00332-7

Figure 2. Protective efficacy of PfSPZ Vaccine against naturally occurring infection.

Figure 2.

Protective efficacy was analysed by time to first positive blood smear, with day 0 starting immediately post receipt of third vaccination. The inverse survival curves include participants who received all three vaccinations and were evaluable for the primary efficacy endpoint (secondary trial outcome). PfSPZ=Plasmodium falciparum sporozoite.